Seer (NASDAQ:SEER – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01, FiscalAI reports. Seer had a negative return on equity of 25.10% and a negative net margin of 484.51%.The company had revenue of $4.12 million during the quarter, compared to analysts’ expectations of $4.00 million. Seer updated its FY 2025 guidance to EPS.
Seer Price Performance
Shares of SEER traded down $0.07 during midday trading on Friday, reaching $2.09. The stock had a trading volume of 252,759 shares, compared to its average volume of 87,300. The company has a market capitalization of $117.75 million, a P/E ratio of -1.54 and a beta of 1.59. The firm’s 50 day moving average price is $2.18 and its 200-day moving average price is $2.11. Seer has a 52 week low of $1.62 and a 52 week high of $2.63.
Insiders Place Their Bets
In related news, CEO Omid Farokhzad sold 33,992 shares of Seer stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $2.04, for a total transaction of $69,343.68. Following the transaction, the chief executive officer directly owned 1,272,068 shares of the company’s stock, valued at $2,595,018.72. The trade was a 2.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.28% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Seer
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Seer currently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on SEER
About Seer
Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.
Recommended Stories
- Five stocks we like better than Seer
- CD Calculator: Certificate of Deposit Calculator
- T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?
- What is a Dividend King?
- Qualcomm Earnings Surprise Wall Street—Here’s What Q4 Could Deliver
- Election Stocks: How Elections Affect the Stock Market
- MarketBeat Week in Review – 11/03 – 11/07
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
